// App-Quantinova.ai

P619 : Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission

Researchers

Presenter

  • D T Rubin

Principal Investigators

  • S Travis

  • B P Abraham

  • N Lawendy

  • H Fan

  • D A Woodworth

  • A J Thorpe

  • C I Nduaka

  • D Quirk

  • W Reinisch

Medical Centers

  • University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA

  • University of Oxford, Translational Gastro-Intestinal Unit- Nuffield Department of Medicine, Oxford, United Kingdom

  • Houston Methodist – Weill Cornell, Division of Gastroenterology and Hepatology, Houston, TX, USA

  • Pfizer Inc, Collegeville, PA

  • Medical University of Vienna, Vienna, Austria

Locations

  • United States

  • United Kingdom

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01465763

  • NCT01458951

  • NCT01458574

  • NCT01470612

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved